Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
The Lancet. Haematology|November 4, 2018
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trialUday R Popat, Rohtesh S Mehta, Roland Bassett, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
HIGH-DOSE CHEMOTHERAPY FOR MULTIPLY OR POOR-RISK RELAPSED GERM-CELL TUMORSYago Nieto, John F Ward, Wayne Hofstetter, et al.
Frontiers in Oncology|November 3, 2022
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanomaJoel Ho, Jane Mattei, Michael Tetzlaff, et al.
Transplantation and Cellular Therapy|June 12, 2026
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDSUday R Popat, Konstantinos Lontos, Roland Bassett, et al.
Nature Medicine|April 4, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Nature Medicine|January 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19<sup>+</sup> B cell tumors: a phase 1/2 trialDavid Marin, Ye Li, Rafet Basar, et al.
Journal for Immunotherapy of Cancer|July 10, 2021
Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutationsFenge Li, Ligang Deng, Kyle R Jackson, et al.
The Journal of Clinical Investigation|August 3, 2016
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cellsPartow Kebriaei, Harjeet Singh, M Helen Huls, et al.
The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Pageof 15